Carson Dalton started his new position as Executive Vice President - Communications & Government Affairs at GSK, a British ...

Onctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces the appointments of Elizabeth Holt as Chief Business Officer (CBO) and Dr Mark ...

The drugmaker has revamped how it packages, promotes and sells certain medicines in an effort to overcome a postpandemic ...

The biotech company is able to genetically modify immune cells, making them capable of attacking tumors directly inside the ...

In early UK corporate news, Phoenix Group lifted its 2026 profit outlook after meeting a cash generation goal sooner than expected. AstraZeneca announced a USD1 billion acquisition. Elsewhere, there ...

The 10 most undervalued stocks from our Best Companies to Own list as of Feb. 27, 2025, were: Here’s a little bit about why ...

NEW YORK CITY, NY / ACCESS Newswire / March 16, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The popular research ...

Larson Financial Group LLC cut its holdings in GSK plc (NYSE:GSK – Free Report) by 52.7% during the fourth quarter, according ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia Therapeutics’ endgame remains focused on pushing the therapy into a wide | ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.